mass ear and eye is going to do clinical studies on cochlear synapathy
Cool. Do you have more details on this?
mass ear and eye is going to do clinical studies on cochlear synapathy
There's always the incentive to be the first to market. Business 101.I disagree, the fact that they are disclosing less information than Frequency does not necessarily mean they are behind.
Hi, who is holding a trial in Australia and are there any details.Frequency is not into phase 1 this year, should be next year. The trial in Australia is not phase 1 for their product.
Frequency TherapeuticsHi, who is holding a trial in Australia and are there any details.
Thank you.
Last data collection is planned for this September. So well probably know in less than a year...we'll have to wait one year before results...while more nice news will come.. it seems like a revolution.
we are living things that were almost science ficcion 5 years ago...im sure that this is the first.
I am not even close to the criteria.
I have high frequency hearing loss.
Do you think they will do further trials for people with not so much damage.
Thank you.
Just the fact that they recently received financial investment from GV is an encouraging sign. They wouldn't invest in a company and it's ideas unless they believed that they were credible and showed promise for the future.
From this interview, I suggested that they consider ototoxicity from the point of view of "prevention", prevention, in the treatment of various ototoxic drugs (aminoglycosides, cisplatin, etc.), and not restoration (regeneration) of hearing loss after the already existing ototoxic damage. If so, then it grieves. I wrote to many companies related to the study of tinnitus and hearing loss, in particular, I was already interested in hearing loss due to ototoxic drugs. But all companies are engaged only in search, preventing ototoxicity, but no more. I also wrote a letter "Decibel terapeutucs" and they answered me very closed. They were advised to subscribe to their twitter. Let's all subscribe, so that they see that their work is necessary for us, and thus we will motivate them! ps. so what about real regeneration while you can talk only in the case of companies "Frequency terapeuticus", or are there any other companies in the world?
Here is the answer to my letter -
"Thank you for your email. Decibel is an early stage company developing drugs for a wide variety of hearing losses through many curative mechanisms. For the purposes of confidentiality, I cannot be more specific about our indications, targets, or timelines. I invite you to keep up with the latest at Decibel byfollowing us on Twitter (@DecibelTx)."
Excuse me, what kind of legal proceedings are we talking about? There are no more such large companies working on regeneration in the world, except frequency and decibel terapeutics? Do you know anything about the treatment of ototoxicity from these companies?I suspect we won't hear much from any of these companies because they are all trying to be the first to market. We might get an update after a trial has been complete. Decibel hasn't even started a trial so it would appear they are behind.
I am following them now on Linkedin. Surprisingly Frequency therapeutics only has 317 followers. Decibel therapeutics has 1207 followers. Also not a lot.Let's all subscribe, so that they see that their work is necessary for us, and thus we will motivate them!
Excuse me, what kind of legal proceedings are we talking about? There are no more such large companies working on regeneration in the world, except frequency and decibel terapeutics? Do you know anything about the treatment of ototoxicity from these companies?
Just a quick shout out to Cheng & Ricci for their achievement in this fieldif they can solve the problem of ototoxic medications creating issues for tinnitus patients, then I would be beyond happy.
A few times now I have had major spikes because of those medications and because I did not know they where ototoxic. So to have something to prevent further damage would already be a HUGE relief and blessing.